Immunovant, Inc. (IMVT) Social Stream



Immunovant, Inc. (IMVT): $18.11

0.34 (+1.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMVT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 400

in industry

Featured Post From StockTwits About IMVT

$SIOX $MAAC $IMVT For intepirdine, isn’t SIOX (f/k/a Axovant) the company that agree to pay GlaxoSmithKline $5M upfront, $160M milestones if comes to market, and 12.5% royalty fees?

Vivek Ramaswamy says that taking on projects later in their development cycle is what provides Roivant Sciences with a sustainable competitive advantage; and, many failed drugs are simply one short phase 3 study away from FDA approval.

He has also stated Alzheimers is the single greatest health threat to the economy. Yes … Axovant was unsuccessful with intepirdine. However, could intepirdine be a game changer?

If SIOX has the development and commercialization rights, it’s hard to believe Roivant isn’t going to acquire for strategic purposes (i) those rights or (ii) all of SIOX ... in connection with Roivant’s commitment to the field of dementia.

Roivant already has a significant ownership interest in SIOX.
SGL_FGHI, published August 12, 2021

What Else are IMVT Traders Talking About?


Other tickers frequently mentioned alongside IMVT is SIOX.

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3907 seconds.